Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Adherium Ltd. ( (AU:ADR) ) just unveiled an announcement.
Adherium director George Baran has significantly increased his indirect shareholding in the company through Trudell Medical Limited, in which he holds a one‑third beneficial interest. Following the latest transaction, his indirect holdings rose by 561,335,130 fully paid ordinary shares issued under the company’s accelerated non‑renounceable entitlement offer at $0.003 per share.
The change takes Baran’s indirect ownership to more than 1.4 billion Adherium shares, alongside existing options, consolidating his financial exposure and aligning his interests more closely with other shareholders. The move underscores continued insider support for the company’s capital‑raising efforts and may be viewed by the market as a signal of confidence in Adherium’s strategic direction and prospects.
The most recent analyst rating on (AU:ADR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Adherium Ltd. stock, see the AU:ADR Stock Forecast page.
More about Adherium Ltd.
Adherium Limited is a medical technology company focused on respiratory health solutions. It develops and supplies digital inhaler monitoring devices and related platforms designed to support medication adherence and disease management for patients with chronic respiratory conditions.
Technical Sentiment Signal: Sell
Current Market Cap: A$13.97M
Find detailed analytics on ADR stock on TipRanks’ Stock Analysis page.